Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Product Name : Apixaban Tiefenbacher
Product Type : HPAPI
Upfront Cash : Inapplicable
October 20, 2022
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Apixaban Tablets (generic for Eliquis®) Approved
Details : Eliquis-Generic (apixaban) is a factor Xa inhibitor anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Product Name : Eliquis-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
August 05, 2021
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TAHO Reports Positive Pivotal Study Results for Oral Dissolving Film TAH3311
Details : TAH3311 (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is being investigated for the treatment of thromboembolic conditions.
Product Name : TAH3311
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TAHO Pharmaceuticals Completes Trial of TAH3311, Oral Dissolving Anticoagulant
Details : TAH3311 (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is being investigated for the treatment of thromboembolic conditions.
Product Name : TAH3311
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TAHO Starts Phase 3 U.S. Trial of TAH3311 Dissolving Antithrombotic Film
Details : TAH3311 is an ODF formulation of apixaban, a factor Xa inhibitor, widely recognized first-line treatment and gold standard for stroke prevention and thrombosis management.
Product Name : TAH3311
Product Type : HPAPI
Upfront Cash : Inapplicable
November 19, 2024
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apixaban
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences Gets USFDA Nod to Market Generic Drug
Details : Apixaban is an oral, reversible, and selective active site inhibitor of FXa. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.
Product Name : Apixaban-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
February 28, 2023
Lead Product(s) : Apixaban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apixaban
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : It alleged that Micro Labs has already listed the apixaban product in 2.5 mg and 3 mg tablet strengths under the probable brand name Apivas on various third party websites and has also applied for registration of the trade mark Apivas before the Indian T...
Product Name : Eliquis
Product Type : HPAPI
Upfront Cash : Inapplicable
August 19, 2021
Lead Product(s) : Apixaban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apixaban
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cambridge Leads National Drug Trial to Prevent Deaths After Covid-19 Patients Leave Hospital
Details : HEAL-COVID will enrol patients when they are discharged from hospital, following their first admission for COVID-19. They will be randomised and given one of two drugs – apixaban and atorvastatin – and their progress tracked.
Product Name : Eliquis
Product Type : HPAPI
Upfront Cash : Inapplicable
March 25, 2021
Lead Product(s) : Apixaban
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apixaban
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Statement on NIH Starting Enrollment for Third Trial of Blood Clotting Treatments for COVID-19
Details : The Phase 3 clinical trials will analyse the use of Bristol Myers Squibb/Pfizer’s anticoagulant, Eliquis (apixaban 2.5mg) in patients discharged from the hospital following a diagnosis of moderate-to-severe Covid-19.
Product Name : Eliquis
Product Type : HPAPI
Upfront Cash : Inapplicable
March 08, 2021
Lead Product(s) : Apixaban
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indoco Receives USFDA Approval for Apixaban Tablets
Details : Apixaban is an anticoagulant, or blood thinner. It is used for patients with health problems caused by a blood clot.
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable